ClinicalTrials.gg
CompletedNCT05609929Updated Nov 21, 2024

Study the Effect of Omeprazole on AB-106 Pharmacokinetics

A Phase 1 interventional study of Multiple administration of omeprazole Single administration of AB-106 in Pharmacokinetic Study, sponsored by Nuvation Bio Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Nuvation Bio Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a single-center, open-label, fixed sequence phase I clinical study. To evaluate the effect of continuous administration of omeprazole magnesium enteric coated tablets on PK after single dose AB-106 capsule administration in Chinese healthy male subjects. This study includes a screening period (1-28 days before administration), treatment period (34 days), and follow-up period ( after the last dose completed 7 ± 3 days). The treatment period of this study was divided into two periods, and the subjects were divided into two groups, 12 subjects in the first group and 10 subjects in the second group. The treatment method and research process of each group of subjects are the same. After the first group of subjects completes the second cycle and is evaluated by the investigator and sponsor, the second group of subjects can start administration. If there are no more than 4 subjects in the first group who have vomiting gastrointestinal reaction (vomiting occurs within 8 hours after each cycle of administration) after completing the two cycles of administration of AB-106 400 mg, they can be added to the second group of subjects, and the number of added subjects shall not exceed the number of subjects who have vomiting gastrointestinal reaction. If more than 4 subjects have gastrointestinal reaction of vomiting, the investigator and sponsor will make a comprehensive evaluation, and can reduce the dosage of AB-106 to 200 mg, and 22 subjects will be included in the trial at one time or supplemented in the second group to complete the 400 mg dose group

02

Conditions studied

  • Pharmacokinetic Study
03

In context

Lead sponsor

Nuvation Bio Inc. is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese male healthy subjects (health refers to the state without abnormalities confirmed by medical history, physical examination, vital signs, 12 lead and clinical laboratory examination).
  2. The age at the time of signing the was between 18 and 55 years old (including the threshold).
  3. When screening, the body weight was more than 50 kg, and the (BMI) was between 19 and 26 kg/m2 (including the cut-off value).
  4. Subjects voluntarily signed the Informed Consent Form (ICF).
  5. Subjects can communicate well with researchers and complete the study according to the protocol.
  6. Male subjects with fertility agree that they and their sexual partners must take effective measures during the study period and within 90 days after the last dose, and agree not to donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or medical history (including drug allergy) of hematology, kidney, endocrine, lung, gastrointestinal, cardiovascular, liver, spirit, nerve or allergic diseases with clinical significance according to the judgment of the investigator.
  2. According to the judgment of the researcher, abnormal laboratory tests with clinical significance (blood routine test, blood biochemical test [fasting], urine routine test, blood coagulation function test).
  3. Systolic blood pressure\<90 mmHg or ≥ 140 mmHg, diastolic blood pressure\<50 mmHg or ≥ 90 mmHg, and the abnormality judged by the investigator is .
  4. People with eye diseases or people with a history of eye diseases who are considered by the investigator to increase the risk of the subject through eye examination.
  5. 12 lead showed >450 ms (msec) or QRS interval>120 msec.
  6. Fever history within 5 days before administration.
  7. People with positive detection of virus surface antigen (HBs Ag), virus antibody (HCV Ab), (HIV) antibody, or Treponema pallidum (TP) antibody.
  8. The food or drug known to be used 28 days before screening is a powerful inhibitor of cytochrome P450 3A4 enzyme (); Known for use 28 days before screening Its drug is CYP3A4 potent inducer; The drug used 28 days before screening and during the study was CYP3A4 substrate with a narrow therapeutic window.
  9. The food or drug known to be used 28 days before screening is the substrate of P-gp
  10. Take Chinese herbal supplements within 28 days before screening; Take any clinical study drug within 3 months or 5 half lives (whichever is longer) before screening; Prescription drugs or over-the-counter drugs and dietary supplements were used within 14 days or 5 half lives (whichever is longer) before screening. As an exception, acetaminophen/paracetamol can be used in a dose of 1 g/day.
  11. Those who have been vaccinated with or attenuated vaccine within 28 days before the start of the trial.
  12. Subjects were unwilling to stop the intake of caffeinated or purine containing foods (such as coffee, tea, cola, chocolate) in each administration cycle from 48 hours before the first administration to the end of the last PK sample collection.
  13. The alcohol intake is more than 14 units/week (1 unit of alcohol is equivalent to 360 mL of beer, 150 mL of wine, or 45 mL of Baijiu), or the subject is unwilling to stop drinking alcohol in each administration cycle, from 48 hours before the first administration to the end of the last PK sample collection, or the alcohol breath test is positive.
  14. Smoking ≥ 5 cigarettes a day, or the subject is unwilling/unable to stop nicotine intake in each dosing cycle from 48 hours before the first dosing to the end of the last PK sample collection.
  15. Major surgery was performed within 6 months before administration.
  16. Blood donation or blood loss ≥ 400 mL within 3 months before administration, or ≥ 200 mL within 1 month before administration
  17. Suffer from gastrointestinal, liver, kidney diseases or other diseases or sequelae known to interfere with drug absorption, distribution, metabolism or excretion within 3 months before the screening period and during the screening period. A history of sensitivity to heparin or heparin induced thrombocytopenia.
  18. Those who have a history of drug abuse or used soft drugs (such as marijuana) or hard drugs (such as heroin, cocaine, etc.) within one year before the study and during the study, or who are positive in drug screening.
  19. Those who are unwilling or unable to comply with the lifestyle guidelines described in this program.
  20. Staff of any institution affiliated to the clinical center and their immediate family members. Immediate relatives refer to those who are related by blood or law, including spouses, children, parents, brothers and sisters.
  21. The researcher judged that it was not suitable to participate in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Omeprazole combined with AB-106 group

    Drug: Multiple administration of omeprazole Single administration of AB-106

Interventions

  • DrugMultiple administration of omeprazole Single administration of AB-106

    Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour

06

What researchers measure

Primary outcomes

  1. Cmax

    plasma drug peak concentration

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  2. AUClast

    area under the plasma drug concentration time curve from 0 to the last measurable drug concentration time point

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  3. AUCinf

    Area under the plasma drug concentration time curve from 0 to infinity (if it can be calculated reliably)

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

Secondary outcomes

  1. Tmax

    Time to reach plasma drug peak concentration

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  2. λ z

    Elimination rate constant

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  3. t1/2

    elimination half-life

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  4. CL/F

    Apparent clearance

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  5. Vz/F

    apparent distribution volume

    Time frame: Day 1 to day15 for both treatment cycle one and cycle two, the total duration is 30 days

  6. Number of adverse events as assessed by CTCAE 5.0

    Number of participants with treatment-related or not-related adverse events as assessed by CTCAE v5.0

    Time frame: Screening period (1-28 days before treatment), treatment period (34 days) and follow-up period (7 ± 3 days after the last visit). The total duration is about 69 days.

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jan 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 8, 2022
StartActual
Nov 2, 2022
Primary completionActual
Jan 20, 2023
CompletionActual
Jan 20, 2023
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05609929
Lead sponsor
Nuvation Bio Inc.
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Nov 2, 2022
Primary completion
Jan 20, 2023
Completion
Jan 20, 2023
Last update
Nov 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion